hi varianto,
stelle hier nur ein paar info`s zu den titeln ipas und airn rein.
Ipass Inc Website Annual Report
3800 Bridge Parkway Phone: +1 650 232-4100
Redwood Shores CALIFORNIA 94065
Fax: +1 650 232-4111
iPass, Inc.. The Group`s principal activity is to provide software-enabled enterprise connectivity services for mobile workers. The primary service offering is designed to enable businesses to provide their employees with secure access from approximately 150 countries to their internal networks through an easy-to-use interface. The software is designed to provide enterprises with a high level of security, the ability to affect and control policy management, and to receive centralized billing and detailed reporting. The Group`s virtual network aggregates over 18,000 network access points in approximately 150 countries. On 05-Oct-2004, the Group acquired Safe3w.
Market cap: $ 362.45M
Shares out: 62.28M
Per share data
Earnings (1 year): 0.28
Current P/E Ratio: 22.38
Cash Flow: $ 0.53
Cash (last quarter): $ 162.07M
nnual Dividend: n/a
Book Value: $ 3.65
EBITDA: $ 8.62M
Management effectiveness
Return on Equity (1 year): 29.57%
Return on assets (1 year): 23.20%
Return on Investment (1 year): n/a
Valuation ratios
Price/Earnings (1 year): 23.29
Price/Book (1 year): 1.75
Price/Cash Flow (1 year): 17.00
Profitability
Gross Margin (1 year): 65.88%
Operating Margin (1 year): 17.68%
rofit Margin (1 year): 11.33%
Settlement
Date Short
Oct. 15, 2004 1,803,709 d.h. ca.2,9% aller aktien
sind geshortet
profitabel, aber charttechnisch angeschlagen. gab ordentlich was auf die rübe nach den letzten q-zahlen.
Airspan Networks Inc Website Annual Report
777 Yamato Road Suite 105 Phone: +1 561 893-8670
Boca Raton FLORIDA 33431
Fax: +1 561 893-8671
Airspan Networks Inc.. The Group`s principal activity is to supply Broadband wireless access equipment to service providers such as internet service providers and other telecommunications users. These systems enable communication service providers to deliver integrated high-speed data and voice services. The systems are based on the Direct Sequence Code Division Multiple Access technology which provides wide area coverage, security and resistance to fading. The integrated solutions include software tools that provide coverage and spectrum optimization and ongoing network management. The Group also offers network installation, integration, training and support services. The Group has international operations in Asia Pacific, Europe, Africa and the Middle East. On 23rd Dec 2003,the Group acquired proximity business from Nortel Networks.
Market cap: $ 231.45M
Shares out: 36.22M
Per share data
Earnings (1 year): -0.65
Current P/E Ratio: n/a
Cash Flow: $ -0.57
Cash (last quarter): $ 47.27M
Annual Dividend: n/a
ook Value: $ 1.11
EBITDA: n/a
Management effectiveness
Return on Equity (1 year): -38.02%
Return on assets (1 year): n/a
Return on Investment (1 year): n/a
Valuation ratios
Price/Earnings (1 year): -9.65
Price/Book (1 year): 5.64
Price/Cash Flow (1 year): -9.14
Profitability
Gross Margin (1 year): 30.62%
Operating Margin (1 year): -35.49%
Profit Margin (1 year): -31.93%
Settlement
Date Short
Oct. 15, 2004 948,900 = ca. 2,5% short
widerstand bei 7 $ muss geknackt werden.
widerstand bei 7 $ aus febr. 2001 und april 2004. danach widerstand bei 8$ aus november 2000.
könnte jetzt auch ein doppeltop gebildet haben...wäre vorsichtig...zahlen kommen am 3.november.
das ist von mir nur eine kleine zusammenfassung. eine kauf- oder verkaufsempfehlung kann und will ich nicht geben, denn ich habe mich nicht ausführlich mit den unternehmen und ihren produkten beschäftigt.
im moment sind die umsätze an den börsen bei steigenden kursen so dünn, so das geringe käufe bzw. verkäufe für grosse schwankungen sorgen können.
für trader interessant:
TPPH früher Napro Biotherapeutics haben ein medikament am markt!!!!
Tapestry Pharmaceuticals Inc Website Annual Report
4840 Pearl East Circle Suite 300W Phone: +1 303 516-8500
Boulder COLORADO 80301
Fax: n/a
Tapestry Pharmaceuticals, Inc. Formerly known as Napro BioTherapeutics, Inc.. The Group`s principal activities were the production, sale and licensing of complex natural product pharmaceuticals. The Group produced and sold paclitaxel, a naturally occurring chemotherapeutic anti-cancer agent found in certain species of yew, or Taxus, trees. It also developed other anti-cancer agents and licenses novel genomic technologies for applications in human therapeutics and diagnostics and agrobiotechnology. The Group primarily used its Gene Editing technology to develop the agents that specifically and precisely edit genes. The products were sold under the trade names ANZATAX (TM), BiotaxTM and NaPro Paclitaxel and are used for injection to treat breast, ovarian and non-small cell lung cancers. The Group sold the Analytical Services group and discontinued and disposed generic injectable paclitaxel business in 2003 and currently conducts only research and development.
Settlement
Date Short
Interest Avg Daily
Share Volume
Days to Cover
Oct. 15, 2004 545,258 50,515 10.79
Market cap: $ 35.29M
Shares out: 33.30M
Per share data
Earnings (1 year): -0.71
Current P/E Ratio: 0.86
Cash Flow: $ -0.43
Cash (last quarter): $ 37.07M
Annual Dividend: n/a
Book Value: $ 1.11
bodenbildung bei 1 $ ?!! aus meiner sicht eine gutes chancen- risiko verhältnis.
was meint ihr?
kosto